Nine Chapters Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Nine Chapters Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-28,900	Closed	-$1.05M	–	297
2016 Q4	$1.05M	Buy	28,900 +23,200	+407%	+$926K	1.77%	10
2016 Q3	$262K	Buy	+5,700	New	+$297K	1.85%	17
2015 Q4	–	Sell	-141,600	Closed	-$8M	–	496
2015 Q3	$8M	Buy	141,600 +96,600	+215%	+$6.26M	0.7%	10
2015 Q2	$2.66M	Sell	45,000 -8,500	-16%	-$524K	0.22%	116
2015 Q1	$3.33M	Buy	53,500 +18,400	+52%	+$1.07M	0.28%	76
2014 Q4	$2.02M	Sell	35,100 -58,000	-62%	-$3.23M	0.17%	154
2014 Q3	$5M	Sell	93,100 -27,800	-23%	-$1.47M	0.45%	41
2014 Q2	$6.34M	Buy	120,900 +116,300	+2,528%	+$5.94M	0.52%	29
2014 Q1	$243K	Buy	+4,600	New	+$213K	0.03%	673
2013 Q3	–	Sell	-18,600	Closed	-$729K	–	906
2013 Q2	$729K	Buy	+18,600	New	+$724K	0.13%	248

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Nine Chapters Capital Management's TEVA Position: Q1 2017 in Review

Nine Chapters Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 28,900 shares — an estimated $1.05M sold.

Nine Chapters Capital Management first reported a position in TEVA in Q2 2013 and held it in 10 quarters. The position peaked at $8M in Q3 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

Nine Chapters Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Nine Chapters Capital Management sold 28,900 Teva Pharmaceuticals shares in Q1 2017, an estimated $1.05M.
Nine Chapters Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Nine Chapters Capital Management's Teva Pharmaceuticals position peaked at $8M in Q3 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on Nine Chapters Capital Management's 13F filing for Q1 2017, filed 8 May 2017.